Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1+
SponsorHospices Civils de Lyon

About this trial

Rare diseases are defined as those that affect one person in 2,000, or around three million people in France. The majority of rare diseases are caused by genetics and tend to be severe when they begin in childhood. Autoimmune and autoinflammatory diseases, such as systemic lupus, juvenile dermatomyositis, and juvenile idiopathic arthritis, are examples of rare pediatric diseases. While autoimmune diseases are characterized by an inappropriate adaptive immune response, autoinflammatory diseases involve an excess of the innate immune response. The precise mechanisms of these diseases are not yet fully understood, but recent research has led to advances in their diagnosis and identification, particularly in early onset and familial forms. However, the rarity of these diseases and limited availability of biological samples pose significant challenges.

This study aims to create a biological collection, which includes primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, that will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases through various research projects.

Eligibility criteria

Qualifiers

Patients

minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years), or syndromic or familial

relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years of age) or syndromic or familial,

weight greater than 5 kg

Disqualifiers

active infection (viral, bacterial, parasitic)

history of neoplasia (< 5 years) or current neoplasia

participants with a personal or family history of autoimmune disease

immunocompromised participant (immune deficiency or transplant recipient)

Trial design

Treatments tested in this trial

  • Blood sample for genetic analysis
  • Blood sample for immunological response assessments
  • Blood sample to identify relevant biomarker of the disease

Treatment groups

400 Participants
are divided into 2 treatment groups

Sponsors and collaborators